The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 ...

In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s ...

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...